HIỆU QUẢ PHÁC ĐỒ GEMCITABINE-CAPECITABINE TRONG ĐIỀU TRỊ UNG THƯ BIỂU MÔ TUYẾN TỤY TẠI BỆNH VIỆN K

Abstract

Objectives: To evaluate the efficacy of gemcitabine-capecitabine regimen in the pancreatic adenocarcinoma treatment at K hospital. Patients and methods: Retrospective and retrospective descriptive study of 36 patients was diagnosed locally advanced or metastatic pancreatic adenocarcinoma at K hospital from January 2017 to April 2022.  Results: The mean age was 57.2 years. The male/female ratio was 1.6/1. Patients with N1 and N2 lymph nodes stage were 44.4% and 19.4%, respectively. The rate of tumor stage T2, T3 and T4 were 16.7%, 36.1% and 47.2%, respectively. Patients with distant metastases accounted for 69,4%. We found that none of patient showed a complete response, the partial response rate was 27.8%, 25.0% of the patients were stable and 47.2% of the patients had progressive disease. The median progession-free survival was 5.5 months (95% Cl, 4.6 to 6.4 months). The median overall survival was 8.5 months (95% CI, 7.8 to 9.2 months). The rate of grade 1/2 neutropenia was 33.3%, grade 3/4 neutropenia was 2.8%. Anemia toxicity occurs quite low, mainly grade 1/2 anemia accounts for 27.8%, no patient had grade 3/4 anemia. Thrombocytopenia also occurred low with 16.7% of patients with grade 1 thrombocytopenia, no patients had grade 2, 3, and 4 thrombocytopenia. Conclusion: The gemcitabine-capecitabine regimen is highly effective, tolerable by the patient. So, it can be widely applied in clinical practice in the treatment of locally advanced or metastatic pancreatic adenocarcinoma.